Asnani, Mukta
Hayer, Katharina E. http://orcid.org/0000-0002-1463-3111
Naqvi, Ammar S.
Zheng, Sisi
Yang, Scarlett Y. http://orcid.org/0000-0002-9398-7363
Oldridge, Derek
Ibrahim, Fadia
Maragkakis, Manolis http://orcid.org/0000-0002-3158-1763
Gazzara, Matthew R.
Black, Kathryn L.
Bagashev, Asen
Taylor, Deanne http://orcid.org/0000-0002-3302-4610
Mourelatos, Zissimos
Grupp, Stephan A.
Barrett, David
Maris, John M.
Sotillo, Elena
Barash, Yoseph
Thomas-Tikhonenko, Andrei http://orcid.org/0000-0002-2739-2206
Article History
Received: 16 May 2019
Revised: 4 September 2019
Accepted: 17 September 2019
First Online: 7 October 2019
Compliance with ethical standards
:
: SAG, DB, JMM, ES, and ATT have an interest in intellectual property “Discovery of CD19 Spliced Isoforms Resistant to CART-19.” This interest does not meet the definition of a reviewable interest under Children’s Hospital of Philadelphia’s (CHOP’s) conflict of interest policy and is therefore not a financial conflict of interest. Furthermore, this intellectual property is held by both CHOP and the University of Pennsylvania and has not been licensed or otherwise commercialized to date. However, should this technology be commercialized in the future, they would be entitled to shares of royalties earned by CHOP per its patent policy.